Investigating β-adrenergic-induced cardiac hypertrophy through computational approach: classical and non-classical pathways
- 359 Downloads
The chronic stimulation of β-adrenergic receptors plays a crucial role in cardiac hypertrophy and its progression to heart failure. In β-adrenergic signaling, in addition to the well-established classical pathway, Gs/AC/cAMP/PKA, activation of non-classical pathways such as Gi/PI3K/Akt/GSK3β and Gi/Ras/Raf/MEK/ERK contribute in cardiac hypertrophy. The signaling network of β-adrenergic-induced hypertrophy is very complex and not fully understood. So, we use a computational approach to investigate the dynamic response and contribution of β-adrenergic mediators in cardiac hypertrophy. The proposed computational model provides insights into the effects of β-adrenergic classical and non-classical pathways on the activity of hypertrophic transcription factors CREB and GATA4. The results illustrate that the model captures the dynamics of the main signaling mediators and reproduces the experimental observations well. The results also show that despite the low portion of β2 receptors out of total cardiac β-adrenergic receptors, their contribution in the activation of hypertrophic mediators and regulation of β-adrenergic-induced hypertrophy is noticeable and variations in β1/β2 receptors ratio greatly affect the ISO-induced hypertrophic response. The model results illustrate that GSK3β deactivation after β-adrenergic receptor stimulation has a major influence on CREB and GATA4 activation and consequent cardiac hypertrophy. Also, it is found through sensitivity analysis that PKB (Akt) activation has both pro-hypertrophic and anti-hypertrophic effects in β-adrenergic signaling.
Keywordsβ-Adrenergic signaling Non-classical pathways Gi/PI3K/Akt/GSK3β pathway Gi/Ras/Raf/MEK/ERK pathway CREB transcription factor GATA4 transcription factor
We convey our thanks to Dr. T. Jamali and Dr. M. Dehghani for their great help.
Compliance with ethical standards
There was no funding for this work.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 10.Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S (1986) Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59:297–309CrossRefGoogle Scholar
- 23.Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S (2014) Heart disease and stroke statistics--2014 update: a report from the American heart association. Circulation 129(3). doi: 10.1161/01.cir.0000441139.02102.80
- 44.O’Connell TD, Ni YG, Lin K-M, Han H, Yan Z (2003) Isolation and culture of adult mouse cardiac myocytes for signaling studies. AFCS Res Rep 1:1–9Google Scholar
- 50.Sato S, Shirato K, Mitsuhashi R, Inoue D, Kizaki T, Ohno H, Tachiyashiki K, Imaizumi K (2013) Intracellular β2-adrenergic receptor signaling specificity in mouse skeletal muscle in response to single-dose β2-agonist clenbuterol treatment and acute exercise. J Physiol Sci 63:211–218CrossRefGoogle Scholar
- 56.Shin S-Y, Kim T, Lee H-S, Kang JH, Lee JY, Cho K-H (2014) The switching role of β-adrenergic receptor signalling in cell survival or death decision of cardiomyocytes. Nature Commun 5:5777Google Scholar